EssexBio

Essex-Bio Group

简繁 EN

COMPANY NEWS

Study Primary Endpoint Met in AURA-2, a Phase 3 Clinical Study of Bevacizumab EB12-20145P (HLX04-O) for the Treatment of Ophthalmic Diseases

2026.06.16

Essex Bio-Technology (1061.HK) 2025 Annual Results at a glance

2026.03.23

Essex Bio-Technology Reports Robust Results for FY2025. Turnover Soars 8.6% to HK$1814 million. Net Profit up 3.5% to HK$ 318.1 million. Total Dividend Increases by 16.7% to HK14 Cents per Share. Multiple Regulatory Approvals and Strategic Collaborations Strengthened Market Position.

2026.03.23

Date

Title

2021-01-29

Essex-Biotechnology Announces Bevacizumab for wAMD Has Received Clinical Trial Approval in Australia

2020-11-23

Essex Bio-Technology Included in Forbes Asia's Best Under A Billion 2020

2020-10-15

Essex and Henlius Entered into a Global Co-Development and Exclusive License Agreement to Jointly Develop Bevacizumab for Treatment of Ophthalmic Diseases

2020-08-25

Essex Bio-Technology and Mitotech Complete Enrollment in VISTA-2 – a Pivotal Phase 3 Clinical Study of SkQ1 for Dry Eye Disease

2020-08-18

Essex Bio-Technology Reports First Half 2020 Financial Results

2020-08-10

Essex Bio-Technology Enters into Global Out-licence Agreement with Kelun-Biotech

2020-04-30

Essex Bio-Technology Joins X-ZELL Seed+ Investment Round

2020-03-17

FY 2019 Profit-After-Tax Up 30.9% to HK$302.5 million,was up 36.5% in RMB denomination

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT